Prudent Precaution in Clinical Trials of Nanomedicines

Journal of Law, Medicine and Ethics

Volumn 40, Issue 4, 2012, Pages 831-840

  Marchant, Gary E ^a   Lindor, Rachel A ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; NANOMEDICINE; RISK MANAGEMENT; SOCIAL BEHAVIOR; UNCERTAINTY; UNITED STATES;

CLINICAL TRIALS AS TOPIC; GOVERNMENT REGULATION; HUMANS; NANOMEDICINE; RISK MANAGEMENT; SOCIAL RESPONSIBILITY; UNCERTAINTY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84872167408     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2012.00711.x     Document Type: Article

References (42)

1. J. J. Koehler and A. D. Gershoff, "Betrayal Aversion: When Agents of Protection Become Agents of Harm, " Organizational Behavior & Human Decision Processes 90, no. 2 (2003): 244-261.
2. G. E. Marchant, "From General Policy to Legal Rule: The Aspirations and Limitations of the Precautionary Principle, " Environmental Health Perspectives 111, no. 14 (2003): 1799-1803.
3. J. B. Wiener, "The Rhetoric of Precaution, " in J. B. Wiener, M. D. Rogers, J. K. Hammitt, and P. H. Sand, eds., The Reality of Precaution: Comparing Risk Regulation in the United States and Europe ( Washington, D.C. : Resources for the Future Press, 2011): 3-35, at 9-11.
4. United Nations Conference on Environment and Development (1992), Rio Declaration on Environment and Development, U.N. Doc. A/CONF.151/5/Rev. 1.
5. C. F. Cranor, "Towards Understanding Aspects of the Precautionary Principle, " Journal of Medicine and Philosophy 29, no. 3 (2004): 259-279, at 261.
6. Science and Environmental Health Network, Wingspread Conference on the Precautionary Principle, January 26, 1998, available at (last visited November 26, 2012).
7. P. Sandin, "Dimensions of the Precautionary Principle, " Human and Ecological Risk Assessment 5, no. 5 (1999): 889-907.
8. Commission of the European Communities (2000), Communication from the Commission on the Precautionary Principle, Brussels, COM(2000) 1.
9. European Environmental Bureau, EEB Position on the Precautionary Principle, December 1999, available at (last visited November 26, 2012).
10. G. E. Marchant and K. L. Mossman, Arbitrary & Capricious: The Precautionary Principle in the European Union Courts (Washington, D.C.: AEI Press, 2004).
11. S. Alban, "The 'Precautionary Principle' as a Guide for Future Drug Development, " European Journal of Clinical Investigation 35, Supp. 1 (2005): 33-44
12. M. Peterson, "The Precautionary Principle Should Not Be Used as a Basis for Decision-Making, "EMBO Reports 8, no. 4 (2007): 305-308
13. J. M. Ritter, I. Harding, and J. B. Warren, "Precaution, Cyclooxygenase Inhibition, and Cardiovascular Risk, "Trends in Pharmacological Sciences 30, no. 10 (2009): 503-508.
14. S. M. Wolf and C. M. Jones, "Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies, " Journal of Nanoparticle Research 13, no. 4 (2011): 1449-1465.
15. C. Sunstein, "Throwing Precaution to the Wind: Why the 'Safe' Choice Can be Dangerous, " Boston Globe, 2008, available at (last visited November 26, 2012).
16. G. A. Kimbrell, "Governance of Nanotechnology and Nanomaterials: Principles, Regulation, and Renegotiating the Social Contract, "Journal of Law, Medicine & Ethics 37, no. 4 (2009): 706-723, at 714
17. H. F. Krug and P. Wick, "Nanotoxicology: An Interdisciplinary Challenge, "Angewandte Chemie International Edition 50, no. 6 (2011): 1260-1278, at 1269-1272.
18. D. B. Warheit, "Debunking Some Myths about Nanotoxicology, " Nano Letters 10, no. 12 (2010): 4777-4782, at 4778.
19. Nanotechnology Task Force, U.S. Food and Drug Administration, Nanotechnology, July 25, 2007, at 11, available at (last visited November 26, 2012).
20. M. A. Hamburg, "FDA's Approach to Regulation of Products of Nanotechnology, " Science 336, no. 6079 (2012): 299-300, at 300.
21. J. P. Holdren, C. R. Sunstein, and I. A. Siddiqui, Policy Principles for the U.S. Decision-Making Concerning Regulation and Oversight of Applications of Nanotechnology and Nanomaterials, Executive Office of the President, 4-5 (June 9, 2011), available at (last visited November 26, 2012).
22. S. T. Stern and S. E. McBride, "Nanotechnology Safety Concerns Revisited, " Toxicological Science 101, no. 1 (2008): 4-21, at 16.
23. L. C. Abbott and A. D. Maynard, "Exposure Assessment Approaches for Engineered Nanomaterials, "Risk Analysis 30, no. 11 (2010): 1634-1644.
24. D. B. Resnik and S. S. Tinkle, "Ethical Issues in Clinical Trials Involving Nanomedicine, " Contemporary Clinical Trials 28, no. 4 (2007): 433-441, at 436.
25. B. Y. S. Kim, J. T. Rutka, and W. C. W. Chan, "Nanomedicine, "New England Journal of Medicine 363, no. 25 (2010): 2434-2443
26. J. Paradise, G. M. Diliberto, A.W. Tisdale, and E. Kokkoli, "Exploring Emerging Nanobiotechnology Drugs and Medical Devices, "Food and Drug Law Journal 63, no. 2 (2008): 407-420.
27. See generally, S. N. Whitney and C. E. Schneider, "A Method to Estimate the Cost in Lives of Ethics Board Review of Biomedical Research, "Journal of Internal Medicine 269, no. 4 (2011): 396-406.
28. M. Ferrari, M. A. Philibert, and W. R. Sanhai, "Nanomedicine and Society, " Clinical Pharmacology & Therapeutics 85, no. 5 (2009): 466-467, at 467.
29. R. Kessler, "Engineered Nanoparticles in Consumer Products: Understanding a New Ingredient, " Environmental Health Perspectives 119, no. 3 (2011): A121-A125, at A122.
30. R. A. Yokel and R. C. McPhail, "Engineered Nanomaterials: Exposures, Hazards, and Risk Prevention, " Journal of Occupational Medicine and Toxicology 6, no. 7 (2011): 1-27, at 2.
31. G. Oberdörster, E. Oberdörster, and J. Oberdörster, "Nanotoxicity: An Emerging Discipline Evolving from Studies of Ultrafine Particles, " Environmental Health Perspectives 113, no. 7 (2005): 823-839, at 837.
32. H. Park and V. H. Grassian, "Commercially Manufactured Engineered Nanomaterials for Environmental and Health Studies: Important Insights Provided by Independent Characterization, " Environmental and Toxicological Chemistry 29, no. 3 (201): 715-721, at 715.
33. A. Maynard, "Don't Define Nanomaterials, " Nature 475, no. 1 (2011): 31, at 31
34. A. D. Maynard, D. B. Warheit, and M. A. Philibert, quot;The New Toxicology of Sophisticated Materials: Nanotoxicology and Beyond,"Toxicological Sciences 120, Suppl. 1 (2011): S109-S129, at S112.
35. R. Barke, "Balancing Uncertain Risks and Benefits in Human Subjects Research, " Science, Technology & Human Values 34, no. 3 (2009): 337-364, at 339.
36. G. E. Marchant, D. J. Sylvester, and K. W. Abbott, "What Does the History of Technology Regulation Teach Us About Nano Oversight, " Journal of Law, Medicine & Ethics 37, no. 4 (2009): 724-731, at 725-726.
37. P. M. Wiedemann and H. Schütz, "The Precautionary Principle and Risk Perception: Experimental Studies in the EMF Area, " Environmental Health Perspectives 113, no. 4 (2005): 402-405.
38. ETC Group, "Nanotech Product Recall Underscores Need for Nanotech Moratorium: Is the Magic Gone?" April 7, 2006, available at (last visited November 26, 2012).
39. M. Agrawal and E. Emanuel, "Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data, " JAMA 290, no. 8 (2003): 1075-1082.
40. J. Kimmelman, "Ethics at Phase 0: Clarifying the Issues, " Journal of Law, Medicine & Ethics 35, no. 8 (2007): 727-733, at 727.
41. Office of Science Policy, National Institutes of Health, "About Recombinant DNA Advisory Committee, "available at (last visited November 26, 2012).
42. E. Soule, "The Precautionary Principle and the Regulation of U.S. Food and Drug Safety, " Journal of Medicine and Philosophy 29, no. 3 (2004): 333-350, at 348-349.